← Back to Search

Powered Wearable Orthotics

MyoPro for Spinal Cord Injury

N/A
Recruiting
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 36 weeks
Awards & highlights

Study Summary

This trial is testing a device called MyoPro to see if it can help people with incomplete spinal cord injuries improve their arm movements. The Department of Defense is funding this study.

Who is the study for?
This trial is for individuals with incomplete spinal cord injuries who have difficulty using their arms. Participants should be able to follow the study procedures and attend all sessions. Specific criteria may apply, but are not listed here.Check my eligibility
What is being tested?
The study is testing a powered wearable orthotic device called MyoPro, comparing its effectiveness in improving arm function and daily activities against conventional therapy methods supported by the Department of Defense.See study design
What are the potential side effects?
Potential side effects were not provided; however, users of MyoPro may experience discomfort or skin issues where the device touches them, muscle fatigue from use, or an adjustment period to the device.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 36 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
GRASSP
Muscle strength measurement
Range of motion of hands and arms
Secondary outcome measures
Brain signals measurement
CUE-Q
Spasticity measurement

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MyoProExperimental Treatment1 Intervention
Receiving MyoMo training in-clinic for 6 weeks, and continuing MyoMo training in-clinic and at home for another 6 weeks.
Group II: ControlActive Control1 Intervention
Receiving conventional therapy in-clinic and using their prescribed static brace (or others) for 6 weeks, and continuing the conventional therapy in-clinic and home using their prescribed static brace (or others) at home for 6 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MyoMo
2019
N/A
~20

Find a Location

Who is running the clinical trial?

Kessler FoundationLead Sponsor
174 Previous Clinical Trials
10,678 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial open to participants who have reached the age of majority, typically considered as 18 years or older?

"To be eligible for this research project, potential candidates must fall within the age bracket of 18 to 80 years old. Notably, there are 44 trials catering to individuals under 18 and an additional 322 catered towards those over the age of 65."

Answered by AI

Which individuals meet the criteria for participation in this research endeavor?

"To be eligible for participation in this clinical study, individuals must have sustained a spinal cord injury and fall within the age range of 18 to 80. Approximately 60 volunteers will be enrolled in this trial."

Answered by AI

Are there any ongoing efforts to enroll patients in this clinical trial?

"That is accurate. Information found on clinicaltrials.gov indicates that this research endeavor is actively seeking suitable participants. The trial was initially listed on October 15th, 2023 and most recently revised on April 4th, 2024. A total of 60 patients are sought from a single site for enrollment in the study."

Answered by AI

What is the total number of individuals currently under research in this clinical trial?

"Indeed, as per the information available on clinicaltrials.gov, this investigation is actively seeking participants. The trial's initial posting date was 10/15/2023 with the most recent update recorded on 4/4/2024. Researchers aim to enroll a total of 60 patients at one specified site."

Answered by AI
~40 spots leftby Oct 2028